Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. 2000

E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
Infectious Diseases Services, Virgen del Rocío University Hospital, Seville, Spain. mcordero@cica.es

Severity criteria for community-acquired pneumonia (CAP) have always excluded patients with human immunodeficiency virus (HIV) infection. A 1-yr, multicenter, prospective observational study of HIV-infected patients with bacterial CAP was done to validate the criteria used in the American Thoracic Society (ATS) guidelines for CAP, and to determine the prognosis-associated factors in the HIV-infected population with bacterial CAP. Overall, 355 cases were included, with an attributable mortality of 9.3%. Patients who met the ATS criteria had a longer hospital stay (p = 0.01), longer duration of fever (p < 0.001), and higher attributable mortality (13.1% versus 3.5%, p = 0.02) than those who did not. Three factors were independently related to mortality: CD4(+) cell count < 100/microl, radiologic progression of disease, and shock. Pleural effusion, cavities, and/or multilobar infiltrates at admission were independently associated with radiologic progression. A prognostic rule based on the five criteria of shock, CD4(+) cell count < 100/microl, pleural effusion, cavities, and multilobar infiltrates had a high negative predictive value for mortality (97.1%). The attributable mortality for severe pneumonia was 11.3%, as compared with 1.3% for nonsevere disease (p = 0.008). The ATS severity criteria are valid in HIV-infected patients with bacterial CAP. Our study provides the basis for identification of patients who may require hospitalization determined by clinical judgment and the five clinical criteria of shock, a CD4(+) cell count < 100/microl, pleural effusion, cavities, and multilobar involvement. These prognostic factors should be validated in independent cohort studies.

UI MeSH Term Description Entries
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D013030 Spain Country located between France on the northeast and Portugal on the west and bordered by the Atlantic Ocean and the Mediterranean Sea. The capital is Madrid. Balearic Islands,Canary Islands
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face

Related Publications

E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
September 1996, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
May 1992, Enfermedades infecciosas y microbiologia clinica,
E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
September 1992, Revista clinica espanola,
E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
February 1998, Journal of clinical microbiology,
E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
February 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
September 1995, Antimicrobial agents and chemotherapy,
E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
November 1995, The European respiratory journal,
E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
June 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
July 1994, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
E Cordero, and J Pachón, and A Rivero, and J A Girón, and J Gómez-Mateos, and M D Merino, and M Torres-Tortosa, and M González-Serrano, and L Aliaga, and A Collado, and J Hernández-Quero, and A Barrera, and E Nuño
January 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!